HWHG(600079) Capital Securities·2024-04-30 12:30Investment Rating - The investment rating for the company is "Accumulate" [2] Core Views - The company has shown steady growth in anesthetic products, with a notable increase in sales from non-surgical departments [2][5] - The core subsidiary, Yichang Renfu, has demonstrated robust performance, with revenue growth driven by the expansion of anesthetic drugs across multiple departments [5] - The company is focusing on "core business concentration," which has led to improved operational quality and a reduction in financial asset volume [5][6] Summary by Sections Financial Performance - In 2023, the company achieved a revenue of 24.525 billion yuan, representing a year-on-year increase of 9.79%, while the net profit attributable to shareholders was 2.134 billion yuan, down 14.07% [5][7] - For Q1 2024, the company reported a revenue of 6.367 billion yuan, up 2.28%, but the net profit attributable to shareholders decreased by 26.89% [5][6] Product Performance - Sales revenue from anesthetic products reached approximately 6.7 billion yuan in 2023, a growth of about 16% year-on-year, with non-surgical departments seeing a significant increase of 39% [5] - The growth in surgical departments is attributed to the recovery of surgical volumes post-pandemic, while the rapid growth in non-surgical departments is linked to the expansion of anesthetic applications in areas such as endoscopy and ICU [5] Subsidiary Performance - Yichang Renfu reported a revenue of 8.060 billion yuan in 2023, up 14.97%, with a net profit of 2.429 billion yuan, an increase of 16.88% [5] - Epic Pharma showed significant improvement with a revenue of 1.058 billion yuan, up 20.92%, and a net profit of 115 million yuan, up 44.03% [5] - Xinjiang Weiyao achieved a revenue of 1.003 billion yuan, a growth of 37.17%, while Sanxia Pharmaceutical reported a revenue of 372 million yuan, down 9.41% [5] Future Outlook - Revenue projections for 2024-2026 are 26.327 billion yuan, 28.339 billion yuan, and 30.441 billion yuan, with year-on-year growth rates of 7.3%, 7.6%, and 7.4% respectively [7] - Net profit forecasts for the same period are 2.182 billion yuan, 2.610 billion yuan, and 3.025 billion yuan, with growth rates of 2.3%, 19.6%, and 15.9% respectively [7]